{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:01:32Z","timestamp":1786114892765,"version":"build-2736575974"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100007313","name":"The University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008067","name":"Exact Sciences Corp","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008562","name":"University of Texas at Austin","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008562","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030841","name":"Exact Sciences Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030841","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.radonc.2026.111573","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T23:45:48Z","timestamp":1778888748000},"page":"111573","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial"],"prefix":"10.1016","volume":"220","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7697-1263","authenticated-orcid":false,"given":"Simona F.","family":"Shaitelman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savitri","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaiane M.","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1779-7007","authenticated-orcid":false,"given":"Heather","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3899-7868","authenticated-orcid":false,"given":"Yu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente","family":"Valero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manickam","family":"Muruganandham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen E.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Belinda M.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-7423","authenticated-orcid":false,"given":"Eileen","family":"Shinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.Fraser","family":"Symmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7935-739X","authenticated-orcid":false,"given":"Wendy A.","family":"Woodward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4390-9372","authenticated-orcid":false,"given":"Melissa P.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chelain R.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman","family":"Buzdar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3145-0023","authenticated-orcid":false,"given":"Puneet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Tamirisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Kuerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2026.111573_b0005","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2026.111573_b0010","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1056\/NEJMoa040587","article-title":"Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer","volume":"351","author":"Hughes","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111573_b0015","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2207586","article-title":"Breast-conserving surgery with or without irradiation in early breast cancer","volume":"388","author":"Kunkler","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.radonc.2026.111573_b0020","unstructured":"Oncology AfCTi. Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (LoTam). (https:\/\/clinicaltrials.gov\/study\/NCT06671912)."},{"key":"10.1016\/j.radonc.2026.111573_b0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1470-2045(24)00661-2","article-title":"Single-modality endocrine therapy versus radiotherapy after breast-conserving surgery in women aged 70 years and older with luminal A-like early breast cancer (EUROPA): a preplanned interim analysis of a phase 3, non-inferiority, randomised trial","volume":"26","author":"Meattini","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0030","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ijrobp.2023.08.065","article-title":"Patient interest in exploring nonsurgical treatment approaches for early-stage breast cancer: a qualitative study","volume":"118","author":"Guhan","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111573_b0035","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.radonc.2026.111573_b0040","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/S1470-2045(15)70168-3","article-title":"Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials","volume":"16","author":"Chang","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0045","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.ijrobp.2010.11.054","article-title":"Long-term outcomes from a prospective trial of stereotactic body radiotherapy for low-risk prostate cancer","volume":"82","author":"King","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111573_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2026.111573_b0055","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijrobp.2017.09.001","article-title":"Stereotactic body radiation therapy as an alternative to transarterial chemoembolization for hepatocellular carcinoma","volume":"100","author":"Sapir","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111573_b0060","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1002\/cncr.34033","article-title":"Stereotactic body radiation therapy for primary liver tumors: an effective liver-directed therapy in the toolbox","volume":"128","author":"Roberts","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2026.111573_b0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/S1470-2045(24)00020-2","article-title":"Stereotactic ablative body radiotherapy for primary kidney cancer (TROG 15.03 FASTRACK II): a non-randomised phase 2 trial","volume":"25","author":"Siva","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0070","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.prro.2022.02.003","article-title":"Radiation therapy for brain metastases: an ASTRO clinical practice guideline","volume":"12","author":"Gondi","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0075","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ijrobp.2023.08.064","article-title":"Utility of stereotactic body radiation therapy in establishing local control for patients with invasive breast cancer not undergoing definitive surgery","volume":"118","author":"Zabrocka","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111573_b0080","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.prro.2023.12.003","article-title":"Locoregional ablative radiation therapy for patients with breast cancer unsuitable for surgical resection","volume":"14","author":"Moore-Palhares","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0085","doi-asserted-by":"crossref","unstructured":"Arriagada R, Mouriesse H, Rezvani A, et al. Radiotherapy alone in breast cancer. Analysis of tumor and lymph node radiation doses and treatment-related complications. The experience of the Gustave-Roussy Institute and the Princess Margaret Hospital. Radiother Oncol 1993;27(1):1-6. DOI: 10.1016\/0167-8140(93)90037-9.","DOI":"10.1016\/0167-8140(93)90037-9"},{"key":"10.1016\/j.radonc.2026.111573_b0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0167-8140(88)90222-8","article-title":"Radical radiotherapy alone in non-operable breast cancer: the major impact of tumor size and histological grade on prognosis","volume":"13","author":"Thomas","year":"1988","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0167-8140(92)90188-Z","article-title":"Primary radiotherapy of breast cancer: treatment results in locally advanced breast cancer and in operable patients selected by positive axillary apex biopsy","volume":"25","author":"Borger","year":"1992","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0100","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/0167-8140(91)90108-S","article-title":"Exclusive radical radiation therapy in breast carcinoma","volume":"20","author":"Dubois","year":"1991","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.radonc.2006.04.005","article-title":"Long-term results of hypofractionated radiotherapy and hormonal therapy without surgery for breast cancer in elderly patients","volume":"79","author":"Courdi","year":"2006","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0110","doi-asserted-by":"crossref","unstructured":"Veluvolu M, Patel M, Narayanasamy G, Kim T. Definitive single fraction stereotactic ablative radiotherapy for inoperable early-stage breast cancer: A case report. Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology 2020;25(5):760-764. DOI: 10.1016\/j.rpor.2020.06.011.","DOI":"10.1016\/j.rpor.2020.06.011"},{"key":"10.1016\/j.radonc.2026.111573_b0115","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S1470-2045(02)00717-9","article-title":"Percutaneous minimally invasive stereotactic primary radiotherapy for breast cancer","volume":"3","author":"Vaidya","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.prro.2018.03.006","article-title":"Durable response of early-stage breast cancer to bilateral definitive SBRT in a medically inoperable patient","volume":"8","author":"Gao","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0125","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.radonc.2026.111573_b0130","unstructured":"NIH NCI, Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Female Breast Cancer Subtypes. (https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html)."},{"key":"10.1016\/j.radonc.2026.111573_b0135","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1016\/j.prro.2020.03.011","article-title":"Consensus on contouring primary breast tumors on mri in the setting of neoadjuvant partial breast irradiation in trials","volume":"10","author":"Vasmel","year":"2020","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0140","doi-asserted-by":"crossref","unstructured":"Bentzen SM, Agrawal RK, Aird EG, et al. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncol 2008;9(4):331-41. (In eng). DOI: S1470-2045(08)70077-9 [pii] 10.1016\/S1470-2045(08)70077-9.","DOI":"10.1016\/S1470-2045(08)70077-9"},{"key":"10.1016\/j.radonc.2026.111573_b0145","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/SLA.0000000000002313","article-title":"A clinical feasibility trial for identification of exceptional responders in whom breast cancer surgery can be eliminated following neoadjuvant systemic therapy","volume":"267","author":"Kuerer","year":"2018","journal-title":"Ann Surg"},{"key":"10.1016\/j.radonc.2026.111573_b0150","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111573_b0155","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.ijrobp.2019.11.406","article-title":"Tumor response after neoadjuvant magnetic resonance guided single ablative dose partial breast irradiation","volume":"106","author":"Vasmel","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2026.111573_b0160","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimator from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Statist Assoc"},{"key":"10.1016\/j.radonc.2026.111573_b0165","doi-asserted-by":"crossref","unstructured":"Brehaut JC, O'Connor AM, Wood TJ, et al. Validation of a decision regret scale. Medical decision making : an international journal of the Society for Medical Decision Making 2003;23(4):281-92. DOI: 10.1177\/0272989X03256005.","DOI":"10.1177\/0272989X03256005"},{"key":"10.1016\/j.radonc.2026.111573_b0170","doi-asserted-by":"crossref","unstructured":"Stanton AL, Krishnan L, Collins CA. Form or function? Part 1. Subjective cosmetic and functional correlates of quality of life in women treated with breast-conserving surgical procedures and radiotherapy. Cancer 2001;91(12):2273-81. (https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11413515).","DOI":"10.1002\/1097-0142(20010615)91:12<2273::AID-CNCR1258>3.0.CO;2-1"},{"key":"10.1016\/j.radonc.2026.111573_b0175","doi-asserted-by":"crossref","unstructured":"Coster S, Poole K, Fallowfield LJ. The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively. Breast Cancer Res Treat 2001;68(3):273-82. (In eng) (http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=11727963).","DOI":"10.1023\/A:1012278023233"},{"key":"10.1016\/j.radonc.2026.111573_b0180","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1200\/JCO.2010.28.4273","article-title":"Genomic index of sensitivity to endocrine therapy for breast cancer","volume":"28","author":"Symmans","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0185","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/clinchem\/hvaa105","article-title":"Technical validity of a customized assay of sensitivity to endocrine therapy using sections from fixed breast cancer tissue","volume":"66","author":"Lau","year":"2020","journal-title":"Clin Chem"},{"key":"10.1016\/j.radonc.2026.111573_b0190","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1093\/clinchem\/hvab068","article-title":"Intra- and interlaboratory reproducibility of the sensitivity to endocrine therapy assay for stage ii\/iii breast cancer","volume":"67","author":"Bossuyt","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.radonc.2026.111573_b0195","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1016\/S1470-2045(22)00613-1","article-title":"Eliminating breast surgery for invasive breast cancer in exceptional responders to neoadjuvant systemic therapy: a multicentre, single-arm, phase 2 trial","volume":"23","author":"Kuerer","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0200","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.ejca.2020.10.015","article-title":"Bridging the age gap in breast cancer. Impacts of omission of breast cancer surgery in older women with oestrogen receptor positive early breast cancer. a risk stratified analysis of survival outcomes and quality of life","volume":"142","author":"Wyld","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111573_b0205","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/s41523-021-00294-w","article-title":"Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a national cancer database analysis","volume":"7","author":"Boyce-Fappiano","year":"2021","journal-title":"npj Breast Cancer"},{"key":"10.1016\/j.radonc.2026.111573_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2025.111236","article-title":"ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives - endorsed by ASTRO","volume":"214","author":"Zamagni","year":"2026","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0215","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1001\/jamasurg.2022.8146","article-title":"Association of surgery with frailty status in older women with early-stage breast cancer","volume":"158","author":"Minami","year":"2023","journal-title":"JAMA Surg"},{"key":"10.1016\/j.radonc.2026.111573_b0220","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1016\/S2666-7568(21)00280-4","article-title":"Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women","volume":"3","author":"Carleton","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"10.1016\/j.radonc.2026.111573_b0225","first-page":"7","article-title":"Treatment constraints for single dose external beam preoperative partial breast irradiation in early-stage breast cancer","volume":"6","author":"Charaghvandi","year":"2017","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0230","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41698-023-00348-1","article-title":"Towards precision radiation oncology: endocrine therapy response as a biomarker for personalization of breast radiotherapy","volume":"7","author":"Udden","year":"2023","journal-title":"npj Precis Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.jgo.2023.101611","article-title":"Assessing patient-reported outcomes (PROs) and patient-related outcomes in randomized cancer clinical trials for older adults: results of DATECAN-ELDERLY initiative","volume":"15","author":"Galvin","year":"2024","journal-title":"J Geriatr Oncol"},{"key":"10.1016\/j.radonc.2026.111573_b0240","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.21873\/invivo.12443","article-title":"Quality of life in early breast cancer patients: a prospective observational study using the FACT-B questionnaire","volume":"35","author":"Ursini","year":"2021","journal-title":"In Vivo"},{"key":"10.1016\/j.radonc.2026.111573_b0245","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/pon.4108","article-title":"Factors associated with self-perceived burden to the primary caregiver in older patients with hematologic malignancies: an exploratory study","volume":"26","author":"Libert","year":"2017","journal-title":"Psychooncology"},{"key":"10.1016\/j.radonc.2026.111573_b0250","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10549-011-1378-5","article-title":"Is the toxicity of adjuvant aromatase inhibitor therapy underestimated? Complementary information from patient-reported outcomes (PROs)","volume":"128","author":"Oberguggenberger","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2026.111573_b0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.breast.2024.103734","article-title":"The impact of age on physical functioning after treatment for breast cancer, as measured by patient-reported outcome measures: a systematic review","volume":"76","author":"Robins","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.radonc.2026.111573_b0260","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1111\/his.15417","article-title":"The prevalence and clinical significance of residual occult breast cancer after neoadjuvant chemotherapy: reassessing surgical pathology in cases initially described as pathological complete response","volume":"86","author":"Ai","year":"2025","journal-title":"Histopathology"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026004123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T22:26:30Z","timestamp":1785968790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026004123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":52,"alternative-id":["S0167814026004123"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111573","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Definitive, stereotactic ablative radiotherapy and endocrine therapy without surgery for select low-risk breast cancers: A prospective, phase II trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111573","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111573"}}